Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Sciele Pharma gets rights to Addrenex's Clonicel

Executive Summary

Start-up Addrenex Pharmaceuticals has licensed Sciele Pharma (prescription drugs for metabolic, cardio, gynecological, and pediatric diseases) exclusive North American marketing rights to Clonicel (clonidine), its Phase III candidate for hypertension and ADHD.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register